Pharmacoeconomic analysis of anemia therapy in cancer patients in real clinical practice of the Russian Federation

• Главные авторы: I. S. Krysanov (Автор), V. S. Krysanova (Автор), V. Yu. Ermakova (Автор)
• Формат: ‌
• Опубликовано: Izdatelstvo OKI, 2019-04-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.
• Notes: 2588-0519; 2618-8473; 10.24411/2588-0519-2018-10054
• Keywords: немиелоидные злокачественные новообразования; анемия; анализ минимизации затрат; эпоэтин альфа; дарбэпоэтин альфа; клинико-экономический анализ; Medical technology; R855-855.5; Pharmacy and materia medica; RS1-441
• Source: Качественная клиническая практика, Vol 0, Iss 4, Pp 4-12 (2019)

Purpose. To conduct a comparative clinical and economic analysis of the use of epoetin alpha (Eralfon) as a therapy of anemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy in the conditions of real clinical practice in the Russian Federation. Method. In the study, a model of care for adult cancer patients with anemia receiving chemotherapy was built, the model takes into account various options for therapy with EPS. Results. The overall cost of treatment of cancer patients with anemia are less in the application of EPS short-acting - epoetin Alpha - 131 609 rubles, compared with the long-acting EPS - darbepoetin alpha 170 of 583.00 RUB, the difference amounted to RUB 38 of 974.00 (-23 %) in favour of epoetin alpha. Summary. Taking into account the data on the equivalent clinical efficacy of epoetin alpha and darbepoetin alpha, the use of the drug epoetin alpha (Eralphon) of domestic production as a therapy for anemia in adult cancer patients receiving chemotherapy in the conditions of real clinical practice in the territory of the Russian Federation is an economically more justified approach to the organization of drug care for cancer patients with anemia.